Why Hims & Hers (HIMS) Stock Is Surging Today—Should You Buy Now?

Interest in Hims & Hers Health Inc. (NYSE: HIMS) has spiked just days before the company’s second-quarter earnings report, sending the telehealth pioneer’s stock up 29 % in July and 166 % year-to-date. Investors are rushing to gauge whether the momentum can hold as management prepares to update the market on August 4. Share-price action and technical setup • Hims stock is attempting to break out of a six-week flat base, hovering near a key buy point identified by growth-stock analysts. • The equity boasts a 98 Relative Strength Rating and an A- Accumulation/Distribution grade, signaling sustained institutional demand. • Despite the run-up, the shares remain roughly 18 % below the January 2021 IPO peak, leaving room for additional upside if fundamentals cooperate. Explosive revenue growth In Q1 2025, Hims delivered revenue of $586 million, a 111 % year-over-year surge, while adjusted EBITDA nearly tripled to $91 million. The company reaffirmed full-year guidance for $2.3 billion–$2.4 billion in sales and boosted its profit outlook to $295 million–$335 million in adjusted EBITDA. What to watch in the Q2 print • Top-line momentum: Consensus calls for 90 %-plus revenue growth as Hims widens its subscription base in hair-loss, mental-health, and dermatology niches. • Weight-management traction: The fallout from its June breakup with Wegovy maker Novo Nordisk raises questions about GLP-1 availability and margins. • Marketing efficiency: Rising customer-acquisition costs are a focus after the company doubled ad spend in Q1. • Cash flow: Hims ended March with $728 million in cash and no debt, giving it ample runway for product launches and potential M&A. Street sentiment and valuation Wall Street maintains a consensus “Hold” with an average 12-month price target of $40.73—about 32 % below the current quote after the recent rally. Targets range from $26 to $68, reflecting wide disagreement on execution risk and multiple expansion potential. Bullish analysts highlight rising earnings estimates—prompting a recent “Bull of the Day” call from Zacks—while skeptics flag intensifying competition from Amazon Clinic and traditional pharmacies entering telehealth. Key risks • Drug-supply uncertainty in weight management. • Regulatory scrutiny as virtual prescribing rules evolve. • Execution hiccups as the firm scales logistics and clinical support. Bottom line Hims stock is entering a pivotal earnings window with technical strength, rapid revenue growth, and a cash-rich balance sheet. If management delivers another beat-and-raise quarter and clarifies its GLP-1 strategy, the shares could push toward new highs; a revenue miss or margin squeeze, however, may spark the first significant pullback of 2025. Traders eyeing telehealth’s next breakout story will be glued to the August 4 release and conference call as the defining catalyst for HIMS in the back half of the year.